Merck & Co., Inc. reported its financial results for the fourth quarter and full year of 2024. Fourth-quarter worldwide sales reached $15.6 billion, a 7% increase compared to the same period in 2023, or 9% excluding foreign exchange impacts. Full-year worldwide sales were $64.2 billion, a 7% increase from 2023, or 10% excluding foreign exchange impacts. KEYTRUDA sales grew by 18% to $29.5 billion for the full year, or 22% excluding foreign exchange impacts. WINREVAIR sales reached $419 million for the full year. Animal Health sales grew by 4% to $5.9 billion for the full year, or 8% excluding foreign exchange impacts. GARDASIL/GARDASIL 9 sales declined by 3% to $8.6 billion for the full year, or 2% excluding foreign exchange impacts. GAAP EPS was $1.48 for the fourth quarter and $6.74 for the full year. Non-GAAP EPS was $1.72 for the fourth quarter and $7.65 for the full year. The company anticipates worldwide sales between $64.1 billion and $65.6 billion for the full year 2025. Non-GAAP EPS is expected to be between $8.88 and $9.03 for the full year 2025.